Literature DB >> 7662028

Human granulocytic ehrlichiosis--New York, 1995.

.   

Abstract

Since 1986, two human tickborne diseases caused by Ehrlichia spp. have been recognized in the United States: human monocytic ehrlichiosis (HME), caused by E. chaffeensis, and human granulocytic ehrlichiosis (HGE), caused by an agent closely related to E. equi (1,2). In June 1995, the Westchester County (New York) Department of Health (WCDOH) received reports from physicians who were treating patients for suspected HGE. In response, the WCDOH sent information to all primary-care physicians in Westchester County describing the clinical and laboratory features of ehrlichiosis (fever, myalgia, headache, leukopenia, and thrombocytopenia) and requested that they voluntarily report suspected cases of ehrlichiosis. This report summarizes an investigation by the New York State Department of Health (NYSDOH) and the WCDOH of suspected ehrlichiosis cases and the clinical characteristics of confirmed and probable cases.

Entities:  

Mesh:

Year:  1995        PMID: 7662028

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   17.586


  15 in total

1.  Ehrlichia chaffeensis and E. sennetsu, but not the human granulocytic ehrlichiosis agent, colocalize with transferrin receptor and up-regulate transferrin receptor mRNA by activating iron-responsive protein 1.

Authors:  R E Barnewall; N Ohashi; Y Rikihisa
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

2.  Human granulocytic anaplasmosis in the United States from 2008 to 2012: a summary of national surveillance data.

Authors:  F Scott Dahlgren; Kristen Nichols Heitman; Naomi A Drexler; Robert F Massung; Casey Barton Behravesh
Journal:  Am J Trop Med Hyg       Date:  2015-04-13       Impact factor: 2.345

3.  Characterization of monoclonal antibodies to the 44-kilodalton major outer membrane protein of the human granulocytic ehrlichiosis agent.

Authors:  H Y Kim; Y Rikihisa
Journal:  J Clin Microbiol       Date:  1998-11       Impact factor: 5.948

4.  Nested PCR assay for detection of granulocytic ehrlichiae.

Authors:  R F Massung; K Slater; J H Owens; W L Nicholson; T N Mather; V B Solberg; J G Olson
Journal:  J Clin Microbiol       Date:  1998-04       Impact factor: 5.948

5.  Expression of interleukin-1beta, tumor necrosis factor alpha, and interleukin-6 in human peripheral blood leukocytes exposed to human granulocytic ehrlichiosis agent or recombinant major surface protein P44.

Authors:  H Y Kim; Y Rikihisa
Journal:  Infect Immun       Date:  2000-06       Impact factor: 3.441

6.  Comparison of two recombinant major outer membrane proteins of the human granulocytic ehrlichiosis agent for use in an enzyme-linked immunosorbent assay.

Authors:  T Tajima; N Zhi; Q Lin; Y Rikihisa; H W Horowitz; J Ralfalli; G P Wormser; K E Hechemy
Journal:  Clin Diagn Lab Immunol       Date:  2000-07

7.  Serologic testing for human granulocytic ehrlichiosis at a national referral center.

Authors:  J A Comer; W L Nicholson; J G Olson; J E Childs
Journal:  J Clin Microbiol       Date:  1999-03       Impact factor: 5.948

8.  Deer ticks (Ixodes scapularis) and the agents of Lyme disease and human granulocytic ehrlichiosis in a New York City park.

Authors:  T J Daniels; R C Falco; I Schwartz; S Varde; R G Robbins
Journal:  Emerg Infect Dis       Date:  1997 Jul-Sep       Impact factor: 6.883

Review 9.  The human ehrlichioses in the United States.

Authors:  J H McQuiston; C D Paddock; R C Holman; J E Childs
Journal:  Emerg Infect Dis       Date:  1999 Sep-Oct       Impact factor: 6.883

10.  Geographic risk for lyme disease and human granulocytic ehrlichiosis in southern New York state.

Authors:  T J Daniels; T M Boccia; S Varde; J Marcus; J Le; D J Bucher; R C Falco; I Schwartz
Journal:  Appl Environ Microbiol       Date:  1998-12       Impact factor: 4.792

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.